Cargando…
Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis
BACKGROUND: Dovitinib is a receptor tyrosine kinase (RTK) inhibitor targeting vascular endothelial growth factor receptors, fibroblast growth factor receptors and platelet-derived growth factor receptor β. Dovitinib is currently in clinical trials for the treatment of hepatocellular carcinoma (HCC)....
Autores principales: | Chen, Zhi-Yuan, Shi, Ming, Peng, Li-Xia, Wei, Wei, Li, Xin-Jian, Guo, Zhi-Xing, Li, Shu-Hong, Zhong, Chong, Qian, Chao-Nan, Guo, Rong-Ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552726/ https://www.ncbi.nlm.nih.gov/pubmed/23228017 http://dx.doi.org/10.1186/1479-5876-10-245 |
Ejemplares similares
-
Neoadjuvant Dovitinib in Early- and Intermediate-Stage Hepatocellular Carcinoma
por: Rizzo, Alessandro, et al.
Publicado: (2022) -
Dovitinib enhances temozolomide efficacy in glioblastoma cells
por: Thanasupawat, Thatchawan, et al.
Publicado: (2017) -
G(q) rather than G(11) preferentially mediates nociceptor sensitization
por: Wirotanseng, Laura Nikita, et al.
Publicado: (2013) -
Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status
por: Gaur, Shikha, et al.
Publicado: (2014) -
Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications
por: Yadav, Shalini S., et al.
Publicado: (2017)